Education
About Us
Working with TipRanks
Follow Us
Longeveron (LGVN)
NASDAQ:LGVN
Earnings Data
Report Date
May 08, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.18Last Year’s EPS
-0.34Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call balanced meaningful clinical and strategic progress (pivotal HLHS readout expected in Q3 2026, IND effectiveness for PDCM, publications/patents, and a $15.9M financing improving runway) against material near-term financial and operational challenges (50% revenue decline, 41% larger net loss, rising R&D/G&A spend, low year-end cash of $4.7M and reliance on additional financing or PRV monetization). While the company has clear catalysts and credible scientific validation, its liquidity profile and widened losses temper the outlook in the near term.Company Guidance
Completed Enrollment of Pivotal HLHS Trial (ELPIS II) and Near-Term Readout
ELPIS II enrollment of 40 patients was completed in June 2025; top-line pivotal Phase IIb results are anticipated in Q3 2026 and, if positive, could support preparation of the company's first BLA and potentially accelerate regulatory approval.
New Capital Raise and Improved Runway
Completed a private placement on March 11, 2026 that raised gross proceeds of approximately $15.9 million; earlier disclosures referenced $15 million secured with a potential second tranche of an additional $15 million upon milestones. Management expects cash plus financing to provide runway into Q4 2026.
Regulatory and Commercial Upside: Rare Pediatric Designation and PRV Eligibility
HLHS program has FDA rare pediatric disease designation and would be eligible for a Priority Review Voucher (PRV) on BLA approval; PRVs have recently sold for between $150 million and $205 million, and the company agreed to pursue sale of an HLHS PRV with investors entitled to 50% of proceeds.
PDCM IND Effective and Planned Registrational Study
Investigational New Drug (IND) for pediatric dilated cardiomyopathy (PDCM) became effective July 2025, enabling advancement to a single pivotal Phase II registrational study; management plans feasibility work in 2026 and potential trial initiation in 2027 with a planned ~70-patient, 1-year design using hierarchical composite endpoints including transplant and hospitalization.
Scientific Validation: Publications and Patents
Company highlighted publications in high-profile journals (Nature Medicine, Cell Stem Cell) and multiple stem cell therapy patents issued globally, supporting scientific credibility and platform value.
Clear Strategic Focus on Partnerships
Management stated intent to pursue strategic partnerships and licensing for Alzheimer’s disease, age-related frailty and other programs to accelerate development, access nondilutive capital and leverage commercialization resources.
LGVN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LGVN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 17, 2026 | $0.96 | $0.98 | +1.67% |
Nov 04, 2025 | $0.80 | $0.76 | -4.75% |
Aug 13, 2025 | $0.86 | $0.76 | -12.21% |
May 08, 2025 | $1.49 | $1.34 | -10.07% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Longeveron (LGVN) report earnings?
Longeveron (LGVN) is schdueled to report earning on May 08, 2026, Before Open (Confirmed).
What is Longeveron (LGVN) earnings time?
Longeveron (LGVN) earnings time is at May 08, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LGVN EPS forecast?
LGVN EPS forecast for the fiscal quarter 2026 (Q1) is -0.18.